The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study

Jian Zhang, Jingzhi Guo, Dan Li, Min Chen, Jie Liu, Chenchen Feng, Qi He, Jing Zhao, Luyao Zhang, Jie Chen, Yongquan Shi, Jian Zhang, Jingzhi Guo, Dan Li, Min Chen, Jie Liu, Chenchen Feng, Qi He, Jing Zhao, Luyao Zhang, Jie Chen, Yongquan Shi

Abstract

Background: Helicobacter pylori (H pylori) infection plays a critical role in gastritis-associated diseases, gastroduodenal ulcers, and even gastric cancer. Studies have shown that probiotics may exhibit antagonistic activity against H pylori.

Methods: This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment. Our research was an open-label, single-arm pilot study of H pylori eradication. Subjects diagnosed with H pylori infection as outpatients at Xijing Hospital were randomized (1:1:1) to receive 8 weeks of therapy with C butyricum (group A), B coagulans (group B), or C butyricum plus B coagulans (group C). H pylori status was assessed 1 to 2 weeks after treatment. The H pylori eradication rate according to intention-to-treat and per-protocol analyses was the primary outcome of study, and the delta over baseline score, adverse events, and compliance were the secondary outcomes. This study was registered at ClinicalTrials.gov (NCT03857425).

Results: A total of 150 subjects were consecutively enrolled from February 2019 to August 2019. The ITT analysis demonstrated that the 3 groups achieved similar eradication rates (18%, 20%, and 26%, respectively, P = .597). The PP analysis yielded a similar result (24.3%, 26.3%, and 32.5%, respectively, P = .703). None of the subjects reported adverse events during treatment. The 3 groups had comparable compliance rates (74% vs 76% vs 80%, P > .05).

Conclusion: C butyricum and B coagulans may effectively inhibit H pylori to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of the study.
Figure 2
Figure 2
The differences in C13-UBT DOB score between the groups before and after the treatment. A, Group A. B, Group B. C, Group C. DOB = delta over baseline.

References

    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:
    1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–86.
    1. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group [published correction appears in Gut 1997 Aug;41(2):276]. Gut 1997;41:8–13.
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143–53.
    1. Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.
    1. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
    1. Dore MP, Cuccu M, Pes GM, et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med 2014;9:649–54.
    1. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut 2015;64:1650–68.
    1. Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist 2018;11:205–11.
    1. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007;137: 3 suppl 2: 812S–8S.
    1. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011;45:960–6.
    1. Ruggiero P. Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol 2014;5:384–91.
    1. Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen? Appl Microbiol Biotechnol 2019;103:1573–88.
    1. Losurdo G, Cubisino R, Barone M, et al. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol 2018;24:139–49.
    1. Isolauri E, Sütas Y, Kankaanpää P, et al. Probiotics: effects on immunity. Am J Clin Nutr 2001;73: 2 suppl: 444S–50S.
    1. Ianiro G, Molina-Infante J, Gasbarrini A. Gastric microbiota. Helicobacter 2015;20: suppl 1: 68–71.
    1. Seth A, Yan F, Polk DB, et al. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2008;294:G1060–9.
    1. Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010;298:G851–9.
    1. Backert S, Neddermann M, Maubach G, et al. Pathogenesis of Helicobacter pylori infection. Helicobacter 2016;21: suppl 1: 19–25.
    1. Perdigòn G, Medina M, Vintiñi E, et al. Intestinal pathway of internalisation of lactic acid bacteria and gut mucosal immunostimulation. Int J Immunopathol Pharmacol 2000;13:141–50.
    1. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60:494–500.
    1. Mukai T, Asasaka T, Sato E, et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002;32:105–10.
    1. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999;60:203–9.
    1. Sgouras D, Maragkoudakis P, Petraki K, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004;70:518–26.
    1. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425–9.
    1. Gotteland M, Poliak L, Cruchet S, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 2005;94:1747–51.
    1. Boonyaritichaikij S, Kuwabara K, Nagano J, et al. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter 2009;14:202–7.
    1. Pantoflickova D, Corthésy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003;18:805–13.
    1. Francavilla R, Lionetti E, Castellaneta SP, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 2008;13:127–34.
    1. Wang KY, Li SN, Liu CS, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004;80:737–41.
    1. Namkin K, Zardast M, Basirinejad F. Saccharomyces boulardii in Helicobacter pylori eradication in children: a randomized trial from Iran. Iran J Pediatr 2016;26:e3768.
    1. Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019;19:1109–20.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera